Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer - PubMed
8 hours ago
- #ovarian cancer
- #combination therapy
- #drug resistance
- Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer.
- Phosphoproteomic analysis identified mTOR and HSF1 pathways as enriched in platinum-resistant ovarian cancer cells.
- The combination of ganetespib (HSP90 inhibitor) and temsirolimus (mTOR inhibitor) with cisplatin synergistically reduced cancer cell growth and increased DNA damage and apoptosis.
- This triple therapy enhanced mouse survival and showed efficacy in platinum-resistant non-small cell lung cancer models.
- The study suggests a novel therapeutic strategy for overcoming platinum resistance in cancer patients.